HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >

Sort by: In order: Results/Page Authors/Record:
Export metadata:
Showing results 1 to 11 of 11
TypeAuthor(s)TitleOther TitlesCitationCitation(alt)Issue Date
articleHarada, Kazuaki; Yamamura, Takahiro; Muto, Osamu; Nakamura, Michio; Sogabe, Susumu; Sawada, Kentaro; Nakano, Shintaro; Yagisawa, Masataka; Muranaka, Tetsuhito; Dazai, Masayoshi; Tateyama, Miki; Kobayashi, Yoshimitsu; Kato, Sosuke; Hatanaka, Kazuteru; Kawamoto, Yasuyuki; Yuki, Satoshi; Sakata, Yuh; Sakamoto, Naoya; Komatsu, YoshitoCorrelation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma : A Multicenter, Retrospective Cohort Study (HGCSG2101)-Journal of clinical medicine-Feb-2023
articleKohya, Risako; Sugiura, Ryo; Yamamoto, Yoshiya; Naruse, Hirohito; Hatanaka, Kazuteru; Kinoshita, Kenji; Abiko, Satoshi; Miyamoto, Shuichi; Suzuki, Kazuharu; Kushibiki, Hanae; Munakata, Satoru; Shimoyama, NorihikoHepatocellular Carcinoma Rupture after Introducing Lenvatinib : An Autopsy Case Report-Internal medicine-1-Apr-2023
articleNakano, Shintaro; Yuki, Satoshi; Kawamoto, Yasuyuki; Nakatsumi, Hiroshi; Ando, Takayuki; Kajiura, Shinya; Yoshikawa, Ayumu; Harada, Kazuaki; Hatanaka, Kazuteru; Tanimoto, Aya; Ishiguro, Atsushi; Honda, Takuya; Dazai, Masayoshi; Sasaki, Takahide; Sakamoto, Naoya; Komatsu, YoshitoImpact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer : a multicenter retrospective study-International journal of clinical oncology-Oct-2021
article (author version)Sugiura, Ryo; Naruse, Hirohito; Yamato, Hiroaki; Kudo, Taiki; Yamamoto, Yoshiya; Hatanaka, Kazuteru; Ito, Jun; Kinoshita, Kenji; Miyamoto, Shuichi; Higashino, Masayuki; Hayasaka, Shuhei; Sakamoto, NaoyaLong-term outcomes and risk factors of recurrent biliary obstruction after permanent endoscopic biliary stenting for choledocholithiasis in high-risk patients-Journal of Digestive Disease-Apr-2020
articleKen, Ito; Satoshi, Yuki; Hiroshi, Nakatsumi; Kawamoto, Yasuyuki; Harada, Kazuaki; Nakano, Shintaro; Saito, Rika; Ando, Takayuki; Sawada, Kentaro; Yagisawa, Masataka; Ishiguro, Atsushi; Dazai, Masayoshi; Iwanaga, Ichiro; Hatanaka, Kazuteru; Sato, Atsushi; Matsumoto, Ryusuke; Shindo, Yoshiaki; Tateyama, Miki; Muranaka, Tetsuhito; Katagiri, Masaki; Yokota, Isao; Sakata, Yuh; Sakamoto, Naoya; Komatsu, YoshitoMulticenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer-Supportive Care in Cancer-1-Jun-2022
article (author version)Komatsu, Yoshito; Yuki, Satoshi; Sogabe, Susumu; Fukushima, Hiraku; Nakatsumi, Hiroshi; Kobayashi, Yoshimitsu; Iwanaga, Ichiro; Nakamura, Michio; Hatanaka, Kazuteru; Miyagishima, Takuto; Kudo, Mineo; Munakata, Masaki; Meguro, Takashi; Tateyama, Miki; Sakata, YuhPhase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer-Acta Oncologica-Sep-2012
articleYasuyuki, Kawamoto; Satoshi, Yuki; Takashi, Meguro; Hatanaka, Kazuteru; Uebayashi, Minoru; Nakamura, Michio; Okuda, Hiroyuki; Iwanaga, Ichiro; Kato, Takashi; Nakano, Shintaro; Sato, Atsushi; Harada, Kazuaki; Oba, Koji; Sakata, Yuh; Sakamoto, Naoya; Komatsu, YoshitoPhase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)-The Oncologist-May-2022
articleNakatsumi, Hiroshi; Komatsu, Yoshito; Muranaka, Tetsuhito; Yuki, Satoshi; Kawamoto, Yasuyuki; Harada, Kazuaki; Dazai, Masayoshi; Tateyama, Miki; Sasaki, Yusuke; Miyagishima, Takuto; Tsuji, Yasushi; Katagiri, Masaki; Nakamura, Michio; Sogabe, Susumu; Hatanaka, Kazuteru; Meguro, Takashi; Kobayashi, Tomoe; Ishiguro, Atsushi; Muto, Osamu; Shindo, Yoshiaki; Kotaka, Masahito; Ando, Takayuki; Takagi, Ryo; Sakamoto, Naoya; Sakata, YuStudy protocol for HGCSG1801 : A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies-Frontiers in oncology-9-Nov-2022
articleKawamoto, Yasuyuki; Komatsu, Yoshito; Yuki, Satoshi; Sawada, Kentaro; Muranaka, Tetsuhito; Harada, Kazuaki; Nakatsumi, Hiroshi; Fukushima, Hiraku; Ishiguro, Atsushi; Dazai, Masayoshi; Hatanaka, Kazuteru; Nakamura, Michio; Iwanaga, Ichiro; Uebayashi, Minoru; Sogabe, Susumu; Kobayashi, Yoshimitsu; Miyagishima, Takuto; Ono, Kota; Sakamoto, Naoya; Sakata, YuhStudy protocol of HGCSG1404 SNOW study : a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer-BMC cancer-8-Dec-2017
articleNakano, Shintaro; Kawamoto, Yasuyuki; Yuki, Satoshi; Harada, Kazuaki; Miyagishima, Takuto; Sogabe, Susumu; Dazai, Masayoshi; Sato, Atsushi; Ishiguro, Atsushi; Nakamura, Michio; Kajiura, Shinya; Takahashi, Yasuo; Tateyama, Miki; Hatanaka, Kazuteru; Tsuji, Yasushi; Sasaki, Takahide; Shindo, Yoshiaki; Kobayashi, Tomoe; Yokota, Isao; Sakamoto, Naoya; Sakata, Yuh; Komatsu, YoshitoStudy protocol of the HGCSG1803 : a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer-BMJ Open-May-2022
articleSugiura, Ryo; Naruse, Hirohito; Yamamoto, Yoshiya; Hatanaka, Kazuteru; Kinoshita, Kenji; Abiko, Satoshi; Miyamoto, Shuichi; Suzuki, Kazuharu; Higashino, Masayuki; Kohya, Risako; Sakamoto, NaoyaVery urgent endoscopic retrograde cholangiopancreatography is associated with early-Revista Espanola de Enfermedades Digestivas: REED-Mar-2022
Showing results 1 to 11 of 11

 

Hokkaido University